NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Never have posted here before but feel the need to interject given all the back-and-forth about the new UCLA trial.
The vaccine the trial is using is NOT DCVax L. It is Prins' own formulation which he describes as "a slightly different version of that" that he himself has developed. How do I know this? I asked him and he gave me that information in a direct communication.
Having said that, not sure what all the kerfluffle is about. As someone mentioned earlier, these institutional trials rarely get past P1 given the financial commitments, and it'll be several years before any hard data emerges from this particular effort.

The issue is getting a but larger as many longs are asserting the trial will be used for approval of -L by the MHRA.

Does Advent even know how to make the UCLA variant? What is the cost to go with separate batches for each dose?